Nyxoah (NYXH) FDA Approvals $1.44 +0.05 (+3.21%) As of 01:32 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock Nyxoah's Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Nyxoah (NYXH). Over the past two years, Nyxoah has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as Genio. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. Genio FDA Regulatory Events Genio is a drug developed by Nyxoah for the following indication: For the Treatment of Obstructive Sleep Apnea. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. FDA approved - August 8,2025Fda Approved Drug: GenioAnnounced Date: August 8, 2025Indication: For the Treatment of Obstructive Sleep ApneaAnnouncementNyxoah SA announced that the U.S. Food and Drug Administration (FDA) has approved the Genio system for a subset of patients with moderate to severe OSA with an Apnea-Hypopnea Index (AHI) of greater than or equal to 15 and less than or equal to 65.AI SummaryNyxoah SA announced that the U.S. Food and Drug Administration has approved the Genio system for treating obstructive sleep apnea in patients with an Apnea-Hypopnea Index (AHI) between 15 and 65. Genio uses bilateral hypoglossal nerve stimulation with a leadless implant, a non-implanted battery solution, and a full-body 1.5T/3T MRI-compatible wearable controller. The wearable component powers, controls, and can be fully upgraded for software and battery without surgery. In the DREAM pivotal trial, Genio met key safety and efficacy endpoints. It achieved a 63.5% AHI responder rate, a 71.3% oxygen desaturation responder rate, and a 70.8% median AHI reduction. Moreover, 82% of participants lowered their AHI to below 15. Genio proved effective in all sleeping positions, cutting AHI by 66.6% when patients lay on their back and by 71% in other positions. Olivier Taelman, Nyxoah’s CEO, said this approval marks a milestone in bringing innovative, simple sleep therapy to U.S. patients with moderate to severe OSA.Read Announcement Nyxoah FDA Events - Frequently Asked Questions Has Nyxoah received FDA approval? As of now, Nyxoah (NYXH) has not received any FDA approvals for its therapy in the last two years. What drugs has Nyxoah submitted to the FDA? In the past two years, Nyxoah (NYXH) has reported FDA regulatory activity for Genio. What is the most recent FDA event for Nyxoah? The most recent FDA-related event for Nyxoah occurred on August 8, 2025, involving Genio. The update was categorized as "FDA approved," with the company reporting: "Nyxoah SA announced that the U.S. Food and Drug Administration (FDA) has approved the Genio system for a subset of patients with moderate to severe OSA with an Apnea-Hypopnea Index (AHI) of greater than or equal to 15 and less than or equal to 65." What conditions do Nyxoah's current drugs treat? Currently, Nyxoah has one therapy (Genio) targeting the following condition: For the Treatment of Obstructive Sleep Apnea. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events Acurx Pharmaceuticals FDA EventsAkebia Therapeutics FDA EventsAltimmune FDA EventsEstrella Immunopharma FDA EventsNiagen Bioscience FDA EventsOmeros FDA EventsOSR FDA EventsRocket Pharmaceuticals FDA EventsTonix Pharmaceuticals FDA EventsZai Lab FDA EventsEli Lilly and Company FDA EventsClearPoint Neuro FDA EventsMoleculin Biotech FDA EventsAprea Therapeutics FDA EventsCapricor Therapeutics FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies KORU Medical Systems FDA Events Apyx Medical FDA Events Avita Medical FDA Events Microbot Medical FDA Events Inovio Pharmaceuticals FDA Events PolyPid FDA Events Nano-X Imaging FDA Events electroCore FDA Events Envoy Medical FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare Stocks FDA progress for NASDAQ:NYXH last updated on 8/11/2025 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredPorter flew 3,300 miles to investigate this systemPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nyxoah SA Please log in to your account or sign up in order to add this asset to your watchlist. Share Nyxoah With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
FDA approved - August 8,2025Fda Approved Drug: GenioAnnounced Date: August 8, 2025Indication: For the Treatment of Obstructive Sleep ApneaAnnouncementNyxoah SA announced that the U.S. Food and Drug Administration (FDA) has approved the Genio system for a subset of patients with moderate to severe OSA with an Apnea-Hypopnea Index (AHI) of greater than or equal to 15 and less than or equal to 65.AI SummaryNyxoah SA announced that the U.S. Food and Drug Administration has approved the Genio system for treating obstructive sleep apnea in patients with an Apnea-Hypopnea Index (AHI) between 15 and 65. Genio uses bilateral hypoglossal nerve stimulation with a leadless implant, a non-implanted battery solution, and a full-body 1.5T/3T MRI-compatible wearable controller. The wearable component powers, controls, and can be fully upgraded for software and battery without surgery. In the DREAM pivotal trial, Genio met key safety and efficacy endpoints. It achieved a 63.5% AHI responder rate, a 71.3% oxygen desaturation responder rate, and a 70.8% median AHI reduction. Moreover, 82% of participants lowered their AHI to below 15. Genio proved effective in all sleeping positions, cutting AHI by 66.6% when patients lay on their back and by 71% in other positions. Olivier Taelman, Nyxoah’s CEO, said this approval marks a milestone in bringing innovative, simple sleep therapy to U.S. patients with moderate to severe OSA.Read Announcement
